Antenatal diagnosis of chromosomal abnormalities is a clinically accepted procedure. Facilities are readily available and increasing numbers of women avail themselves of the technology. Despite general medical acceptance (15, 30–32, 46, 56), however, problems remain both for investigators as well as for individuals responsible for genetic health care delivery. The purpose of this article, which updates the author's previous communications (39–41), is to review current cytogenetic indications for antenatal diagnosis, to consider potential additional indications, and to speculate briefly on future directions.